URGN Chief Medical Officer Mark Schoenberg Sells $350K of Stock

Mark Schoenberg Sells URGN Stock

Chief Medical Officer Mark Schoenberg sold 10,000 shares of UroGen Pharma Ltd. (NasdaqGM: URGN) on June 22, 2026. The stock was sold at a price of $35.01 per share, reaching a total value of $350,100. This transaction was carried out under a pre-arranged trading plan.

Insider Buying and Selling at UroGen Pharma Ltd.

The sale by Schoenberg comes alongside notable buying activity from other insiders at the biotechnology firm. On June 22, 2026, Stuart Holden acquired 20,000 shares, while Arie Belldegrun also picked up 20,000 shares. Additional purchases on the same day included 10,000 shares bought by Robinson James JR., 10,000 shares by Cynthia Butitta, 10,000 shares by Leana Wen, and 10,000 shares by Wildman Daniel George.

Stock Price Context

UroGen Pharma shares recently traded near $35.80. The company has a 52-week low of $15.86 and a 52-week high of $50.81. Its shares move relative to a 50-day moving average of $43.77 and a 200-day moving average of $29.10.

Recent Earnings Performance

For its financial results, the company reported $188.73 million in revenue with a revenue growth rate of 1.99%. It posted earnings per share of negative $1.97 alongside a net margin of negative 51.7%. The firm operates with a forward P/E ratio of 15.46. The next financial release is scheduled for November 5, 2026.

Wall Street Analyst Outlook

Analyst coverage includes several updates from major financial institutions following recent operational updates. On July 16, 2026, Oppenheimer maintained an outperformer rating with a $50.00 price target. Guggenheim kept its buy rating on July 21, 2026, lifting its target to $42.00. TD Cowen maintained a buy rating on August 5, 2026, with a $60.00 price target. On August 6, 2026, Guggenheim maintained a buy rating and raised its target to $58.00, while HC Wainwright & Co. kept a buy rating and raised its target to $75.00. The stock holds a consensus strong buy rating and an average price target of $60.00 across eight analyst opinions.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biotechnology company focused on developing therapies for specialty and urothelial cancers. It uses proprietary technologies like RTGel to deliver treatments for conditions such as non-muscle invasive bladder cancer. The firm works to advance several clinical-stage product candidates through ongoing trials.

What to Watch at URGN

Investors will look ahead to the company's next earnings report on November 5, 2026, for further details on revenue and clinical progress. Future SEC filings will provide additional updates on insider transactions and institutional holdings.